CNS & Clinical Pharmacology

Human Abuse Liability / Human Abuse Potential (HAL/HAP) Studies

Human Abuse Liability (HAL) and Human Abuse Potential (HAP) studies evaluate whether an investigational drug has characteristics that could lead to misuse or abuse. CenExel partners with sponsors to conduct scientifically rigorous, regulatory-focused studies that generate the safety, pharmacokinetic, pharmacodynamic, and subjective effect data needed to support global drug development programs.

Studies Conducted
0 +
Trial Participants
0 +
Active Centers
0
Overview

Advancing Human Abuse Liability & Human Abuse Potential Research

CenExel conducts Human Abuse Liability (HAL) and Human Abuse Potential (HAP) studies that support the development of CNS-active therapies and other compounds requiring abuse potential evaluation. Our experienced clinical pharmacology teams execute carefully designed protocols that generate reliable data for regulatory submissions and informed benefit-risk assessments.

From protocol development through study completion, we deliver high-quality operational execution, experienced investigators, and participant safety oversight while maintaining strict regulatory compliance.

Conditions Covered

Human Abuse Liability Studies We Support

Our clinical research network supports Human Abuse Liability and Human Abuse Potential studies for investigational therapies across multiple therapeutic areas, including:

  • CNS Disorders
  • Pain Management
  • Neurology
  • Psychiatry
  • Sleep Disorders
  • Substance Use Disorders
  • Rare Neurological Diseases
  • Analgesics
Our Approach

Why Sponsors Choose CenExel for HAL / HAP Studies

Our experienced clinical pharmacology teams combine scientific expertise with operational excellence to support Human Abuse Liability studies that meet sponsor objectives and regulatory expectations.

01

Regulatory Expertise

Deep understanding of FDA guidance and global regulatory expectations for Human Abuse Liability and Human Abuse Potential studies.

02

Specialized Clinical Pharmacology Experience

Experienced investigators and dedicated research teams conduct complex inpatient studies with standardized assessments and participant safety at the forefront.

03

High-Quality PK/PD & Subjective Assessments

Robust pharmacokinetic, pharmacodynamic, cognitive, and subjective effect evaluations generate reliable data to support abuse potential assessments.

04

Efficient Study Execution

Dedicated project management, experienced site staff, and streamlined operations help sponsors maintain development timelines while ensuring high-quality data collection.

Phase Coverage

Supported HAL / HAP Trial Phases

CenExel supports Human Abuse Liability and Human Abuse Potential studies throughout clinical development, providing specialized clinical pharmacology expertise, experienced investigators, and high-quality operational execution for regulatory-focused research.

Active across all phases
  • Phase I
  • Phase II
  • Phase III
  • Phase IV

Our experienced respiratory research network helps sponsors execute studies efficiently across hospital and acute-care environments while maintaining high-quality patient care and data integrity.

Let’s Advance Your Next Study

Looking for an experienced research partner for Human Abuse Liability or Human Abuse Potential studies? Connect with CenExel to learn how our clinical pharmacology expertise and nationwide research network can support your development program.

Explore Our Network

Discover CenExel’s Centers of Excellence and find the locations, therapeutic expertise, and capabilities that align with your clinical development needs.

Our Blog